Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
, Press Release, Oct 2020
Bamlanivimab/etesevimab for COVID-19
24th treatment shown to reduce risk in
May 2021, now with p = 0.00049 from 22 studies, recognized in 11 countries.
Efficacy is variant dependent.
No treatment is 100% effective.
Protocols combine treatments.
ACTIV-3 intermin analysis shows LY-CoV555 is unlikely to help hospitalized patients. ACTIV-2, BLAZE-1 and BLAZE-2 trials remain ongoing.
Lilly et al., 26 Oct 2020, preprint, 1 author.